Aeon Global Health Corp. Receivables Turnover Ratio (ADAT), from the third quarter 2019 to the third quarter 2017 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Aeon Global Health Corp.  (ADAT)
 

Aeon Global Health Accounts Receivables Turnover Ratio from the third quarter 2019 to the third quarter 2017

Quarterly Results, Trends, Rankings, Statistics


Aeon Global Health Corp.'s ability to collect accounts receivable sequentially worsen to 8.83, indicating more challenging environment then in the second quarter 2018, but still, it is a far cry from any concerns. Aeon Global Health's Accounts Receivable average collection period in the Mar 31 2019 quarter, has increased to 41 days, from 28 days, in the Dec 31 2017 quarter.

If we take a look into Healthcare sector 87 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2019 from to 1071.

What is Receivable Turnover Ratio?
What is Aeon Global Health Corp. Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADAT Receivables Turnover Ratio (Mar 31 2019)
III. Quarter		 (Dec 31 2017)
II. Quarter		 (Sep 30 2017)
I. Quarter		 (Jun 30 2017)
IV. Quarter		 (Dec 31 2016)
II. Quarter
Y / Y Receivable Change 142.02 % -3.87 % -61.94 % -58.1 % 133.11 %
Y / Y Revenue Change -47.05 % -8.58 % -87.85 % -31.7 % 234.48 %
Receivable Turnover Ratio (TTM) 8.83 13.04 13.18 24.89 21.45
ADAT's Total Ranking # 1071 # # # #
Accounts Receivable average collection period days 41 28 28 15 17
Seq. Receivable Change 5.39 % 202.62 % -20.12 % -4.99 % -58.14 %
Seq. Revenue Change -53.22 % 64.72 % -10.66 % -23.09 % -19.23 %


Receivable Turnover Company Ranking
Within: No.
Laboratory Analytical Instruments Industry # 4
Healthcare Sector # 88
Overall Market # 1071

Receivable Turnover Ratio Statistics
High Average Low
1.1 0.88 0.55
(Mar 31 2019)   (Sep 30 2017)





ADAT Company Profile • Back to ADAT Efficiency Comparisons • Compare ADAT Receivables Turnover Ratio to its Competitors

Financial Statements
Aeon Global Health's Accounts Receivable $ 3 Millions Visit ADAT's Balance sheet
Aeon Global Health's Sales TTM $ 15 Millions Visit ADAT's Income Statement
Sources of ADAT's Revenues Visit ADAT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Laboratory Analytical Instruments Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ADAT's Receivable Turnover Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ADAT's Growth Rates ADAT's Roa ADAT's Inventory Turnover Ratio ADAT's Dividend Comparisons
ADAT's Profitability Ratios ADAT's Roi ADAT's Asset Turnover Ratio ADAT's Dividend Growth
ADAT's Valuation Ratios ADAT's Roe ADAT's Financial Strength Ratios ADAT's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2019, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Mar 31 2019 Receivable at quarter ending Mar 31 2019
Vystar Corporation  16.00 $ 0.530  Millions$ 0.033  Millions
Miragen Therapeutics Inc   15.90 $ 3.974  Millions$ 0.250  Millions
Rigel Pharmaceuticals Inc  15.67 $ 57.133  Millions$ 3.646  Millions
Chemed Corporation  15.46 $ 1,805.506  Millions$ 116.821  Millions
Sutro Biopharma Inc   15.45 $ 41.255  Millions$ 2.670  Millions
Tvardi Therapeutics Inc   15.26 $ 17.851  Millions$ 1.170  Millions
Chimerix Inc   15.22 $ 8.774  Millions$ 0.577  Millions
Emmaus Life Sciences Inc   15.11 $ 1.581  Millions$ 0.105  Millions
Ainos Inc   14.99 $ 0.025  Millions$ 0.002  Millions
Geovax Labs Inc   14.91 $ 1.106  Millions$ 0.074  Millions
Akebia Therapeutics Inc   14.23 $ 234.478  Millions$ 16.480  Millions
Viskase Holdings inc   14.13 $ 6.852  Millions$ 0.485  Millions
Otonomy Inc   14.06 $ 0.636  Millions$ 0.045  Millions
Neuronetics Inc   13.76 $ 55.352  Millions$ 4.023  Millions
Ibio inc   13.62 $ 1.314  Millions$ 0.097  Millions
Regeneron Pharmaceuticals Inc   12.93 $ 6,911.115  Millions$ 534.608  Millions
Organogenesis Holdings Inc   12.92 $ 215.043  Millions$ 16.647  Millions
Sangamo Therapeutics Inc   12.92 $ 79.886  Millions$ 6.186  Millions
Portola Pharmaceuticals inc   12.62 $ 55.655  Millions$ 4.409  Millions
Mannkind Corporation  12.51 $ 41.841  Millions$ 3.344  Millions
Travere Therapeutics Inc   12.48 $ 165.384  Millions$ 13.253  Millions
Silk Road Medical Inc   12.47 $ 12.766  Millions$ 1.024  Millions
H cyte Inc  12.43 $ 1.998  Millions$ 0.161  Millions
Dmk Pharmaceuticals Corporation  12.36 $ 16.813  Millions$ 1.360  Millions
Immucell Corporation  12.35 $ 12.516  Millions$ 1.014  Millions
Corcept Therapeutics Inc  12.18 $ 258.417  Millions$ 21.218  Millions
Scienture Holdings Inc   12.08 $ 4.491  Millions$ 0.372  Millions
Edesa Biotech Inc   12.05 $ 0.298  Millions$ 0.025  Millions
Neurometrix Inc   11.93 $ 14.270  Millions$ 1.196  Millions
Novaccess Global Inc  11.85 $ 1.397  Millions$ 0.118  Millions

Date modified: 2026-09-08T15:22:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.